| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA372399
Max Phase: Preclinical
Molecular Formula: C21H26Cl2N6O
Molecular Weight: 449.39
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=C([C@H]1CCCCN1)N1CCN(c2nccc(NCc3ccc(Cl)cc3Cl)n2)CC1
Standard InChI: InChI=1S/C21H26Cl2N6O/c22-16-5-4-15(17(23)13-16)14-26-19-6-8-25-21(27-19)29-11-9-28(10-12-29)20(30)18-3-1-2-7-24-18/h4-6,8,13,18,24H,1-3,7,9-12,14H2,(H,25,26,27)/t18-/m1/s1
Standard InChI Key: SDCCQLHNQKMWFL-GOSISDBHSA-N
Associated Targets(Human)
C-C chemokine receptor type 4 2819 Activities
Associated Targets(non-human)
L1.2 32 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mus musculus 284745 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 449.39 | Molecular Weight (Monoisotopic): 448.1545 | AlogP: 3.19 | #Rotatable Bonds: 5 |
| Polar Surface Area: 73.39 | Molecular Species: BASE | HBA: 6 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 8.90 | CX LogP: 3.48 | CX LogD: 1.85 |
| Aromatic Rings: 2 | Heavy Atoms: 30 | QED Weighted: 0.73 | Np Likeness Score: -1.58 |
References
| 1. Purandare AV, Wan H, Gao A, Somerville J, Burke C, Vaccaro W, Yang X, McIntyre KW, Poss MA.. (2006) Optimization of CCR4 antagonists: side-chain exploration., 16 (1): [PMID:16236499] [10.1016/j.bmcl.2005.09.022] |
| 2. Purandare AV, Wan H, Somerville JE, Burke C, Vaccaro W, Yang X, McIntyre KW, Poss MA.. (2007) Core exploration in optimization of chemokine receptor CCR4 antagonists., 17 (3): [PMID:17098428] [10.1016/j.bmcl.2006.10.091] |
| 3. Shukla L, Ajram LA, Begg M, Evans B, Graves RH, Hodgson ST, Lynn SM, Miah AH, Percy JM, Procopiou PA, Richards SA, Slack RJ.. (2016) 2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis., 115 [PMID:26991939] [10.1016/j.ejmech.2016.02.058] |
Source
Source(1):